Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers
- PMID: 21593217
- PMCID: PMC3652640
- DOI: 10.1093/hmg/ddr226
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers
Abstract
Two single nucleotide polymorphisms (SNPs) at 6q25.1, near the ESR1 gene, have been implicated in the susceptibility to breast cancer for Asian (rs2046210) and European women (rs9397435). A genome-wide association study in Europeans identified two further breast cancer susceptibility variants: rs11249433 at 1p11.2 and rs999737 in RAD51L1 at 14q24.1. Although previously identified breast cancer susceptibility variants have been shown to be associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers, the involvement of these SNPs to breast cancer susceptibility in mutation carriers is currently unknown. To address this, we genotyped these SNPs in BRCA1 and BRCA2 mutation carriers from 42 studies from the Consortium of Investigators of Modifiers of BRCA1/2. In the analysis of 14 123 BRCA1 and 8053 BRCA2 mutation carriers of European ancestry, the 6q25.1 SNPs (r(2) = 0.14) were independently associated with the risk of breast cancer for BRCA1 mutation carriers [hazard ratio (HR) = 1.17, 95% confidence interval (CI): 1.11-1.23, P-trend = 4.5 × 10(-9) for rs2046210; HR = 1.28, 95% CI: 1.18-1.40, P-trend = 1.3 × 10(-8) for rs9397435], but only rs9397435 was associated with the risk for BRCA2 carriers (HR = 1.14, 95% CI: 1.01-1.28, P-trend = 0.031). SNP rs11249433 (1p11.2) was associated with the risk of breast cancer for BRCA2 mutation carriers (HR = 1.09, 95% CI: 1.02-1.17, P-trend = 0.015), but was not associated with breast cancer risk for BRCA1 mutation carriers (HR = 0.97, 95% CI: 0.92-1.02, P-trend = 0.20). SNP rs999737 (RAD51L1) was not associated with breast cancer risk for either BRCA1 or BRCA2 mutation carriers (P-trend = 0.27 and 0.30, respectively). The identification of SNPs at 6q25.1 associated with breast cancer risk for BRCA1 mutation carriers will lead to a better understanding of the biology of tumour development in these women.
Figures



References
-
- Ahmed S., Thomas G., Ghoussaini M., Healey C.S., Humphreys M.K., Platte R., Morrison J., Maranian M., Pooley K.A., Luben R., et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat. Genet. 2009;41:585–590. doi:10.1038/ng.354. - DOI - PMC - PubMed
-
- Easton D.F., Pooley K.A., Dunning A.M., Pharoah P.D., Thompson D., Ballinger D.G., Struewing J.P., Morrison J., Field H., Luben R., et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447:1087–1093. doi:10.1038/nature05887. - DOI - PMC - PubMed
-
- Hunter D.J., Kraft P., Jacobs K.B., Cox D.G., Yeager M., Hankinson S.E., Wacholder S., Wang Z., Welch R., Hutchinson A., et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 2007;39:870–874. doi:10.1038/ng2075. - DOI - PMC - PubMed
-
- Stacey S.N., Manolescu A., Sulem P., Rafnar T., Gudmundsson J., Gudjonsson S.A., Masson G., Jakobsdottir M., Thorlacius S., Helgason A., et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 2007;39:865–869. doi:10.1038/ng2064. - DOI - PubMed
-
- Stacey S.N., Manolescu A., Sulem P., Thorlacius S., Gudjonsson S.A., Jonsson G.F., Jakobsdottir M., Bergthorsson J.T., Gudmundsson J., Aben K.K., et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 2008;40:703–706. doi:10.1038/ng.131. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 CA069417/CA/NCI NIH HHS/United States
- U01 CA069638/CA/NCI NIH HHS/United States
- CA128978/CA/NCI NIH HHS/United States
- R01-CA102776/CA/NCI NIH HHS/United States
- U01 CA69417/CA/NCI NIH HHS/United States
- 019511/CAPMC/ CIHR/Canada
- 11174/CRUK_/Cancer Research UK/United Kingdom
- R01-CA74415/CA/NCI NIH HHS/United States
- N02PC45022-46/PC/NCI NIH HHS/United States
- A10119/CRUK_/Cancer Research UK/United Kingdom
- R01 CA083855/CA/NCI NIH HHS/United States
- P50 CA058207/CA/NCI NIH HHS/United States
- R01 CA102776/CA/NCI NIH HHS/United States
- 10119/CRUK_/Cancer Research UK/United Kingdom
- C1287/A11990/CRUK_/Cancer Research UK/United Kingdom
- U01 CA069446/CA/NCI NIH HHS/United States
- A10124/CRUK_/Cancer Research UK/United Kingdom
- 10124/CRUK_/Cancer Research UK/United Kingdom
- C5047/A8385/CRUK_/Cancer Research UK/United Kingdom
- U01 CA069467/CA/NCI NIH HHS/United States
- RFA-CA-06-503/CA/NCI NIH HHS/United States
- 11022/CRUK_/Cancer Research UK/United Kingdom
- N02-CP-11019-50/CP/NCI NIH HHS/United States
- C12292/A11174/CRUK_/Cancer Research UK/United Kingdom
- U01 CA069398/CA/NCI NIH HHS/United States
- R01 CA128978/CA/NCI NIH HHS/United States
- N02 CP011019/CP/NCI NIH HHS/United States
- N02 CP065504/CP/NCI NIH HHS/United States
- U01 CA069631/CA/NCI NIH HHS/United States
- U01 CA69398/CA/NCI NIH HHS/United States
- R01-CA083855/CA/NCI NIH HHS/United States
- U01 CA69638/CA/NCI NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- A6187/CRUK_/Cancer Research UK/United Kingdom
- CA-06-503/CA/NCI NIH HHS/United States
- U01 CA69446/CA/NCI NIH HHS/United States
- U01 CA69631/CA/NCI NIH HHS/United States
- R01 CA074415/CA/NCI NIH HHS/United States
- 10118/CRUK_/Cancer Research UK/United Kingdom
- C1287/A10118/CRUK_/Cancer Research UK/United Kingdom
- U01 CA69467/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous